These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 10824626)
21. Suggested dosage rates of melarsoprol in the treatment of mice experimentally infected with Trypanosoma brucei gambiense. Mbati PA; Hirumi K; Inoue N; Situakibanza NH; Hirumi H Onderstepoort J Vet Res; 2000 Mar; 67(1):71-4. PubMed ID: 10843325 [TBL] [Abstract][Full Text] [Related]
22. Effectiveness of melarsoprol and eflornithine as first-line regimens for gambiense sleeping sickness in nine Médecins Sans Frontières programmes. Balasegaram M; Young H; Chappuis F; Priotto G; Raguenaud ME; Checchi F Trans R Soc Trop Med Hyg; 2009 Mar; 103(3):280-90. PubMed ID: 18947846 [TBL] [Abstract][Full Text] [Related]
23. Distribution and quantitation of the anti-trypanosomal diamidine 2,5-bis(4-amidinophenyl)furan (DB75) and its N-methoxy prodrug DB289 in murine brain tissue. Sturk LM; Brock JL; Bagnell CR; Hall JE; Tidwell RR Acta Trop; 2004 Jul; 91(2):131-43. PubMed ID: 15234662 [TBL] [Abstract][Full Text] [Related]
24. Determination of melarsoprol in biological fluids by high-performance liquid chromatography and characterisation of two stereoisomers by nuclear magnetic resonance spectroscopy. Ericsson O; Schweda EK; Bronner U; Rombo L; Fridén M; Gustafsson LL J Chromatogr B Biomed Sci Appl; 1997 Mar; 690(1-2):243-51. PubMed ID: 9106049 [TBL] [Abstract][Full Text] [Related]
25. Comparison of the in vitro drug sensitivity of Trypanosoma brucei gambiense strains from West and Central Africa isolated in the periods 1960-1995 and 1999-2004. Likeufack AC; Brun R; Fomena A; Truc P Acta Trop; 2006 Nov; 100(1-2):11-6. PubMed ID: 17078916 [TBL] [Abstract][Full Text] [Related]
26. Clinical presentation and treatment outcome of sleeping sickness in Sudanese pre-school children. Eperon G; Schmid C; Loutan L; Chappuis F Acta Trop; 2007 Jan; 101(1):31-9. PubMed ID: 17207760 [TBL] [Abstract][Full Text] [Related]
27. The melaminophenyl arsenicals melarsoprol and melarsen oxide interfere with thiamine metabolism in the fission yeast Schizosaccharomyces pombe. Schweingruber ME Antimicrob Agents Chemother; 2004 Sep; 48(9):3268-71. PubMed ID: 15328083 [TBL] [Abstract][Full Text] [Related]
28. In vivo evaluation of sixteen plant extracts on mice inoculated with Trypanosoma brucei gambiense. Youan BB; Coulibaly S; Miezan TB; Doua F; Bamba M Bull World Health Organ; 1997; 75(4):343-8. PubMed ID: 9342893 [TBL] [Abstract][Full Text] [Related]
29. The monitoring of trypanocidal treatment with a sensitive ELISA method for measuring melarsoprol levels in serum and in cerebrospinal fluids. Maes L; Vanderveken M; Hamers R; Doua F; Cattand P Ann Soc Belg Med Trop; 1988 Sep; 68(3):219-31. PubMed ID: 3223784 [No Abstract] [Full Text] [Related]
30. [Three patients with African sleeping sickness following a visit to Tanzania]. Mendonça Melo M; Rasica M; van Thiel PP; Richter C; Kager PA; Wismans PJ Ned Tijdschr Geneeskd; 2002 Dec; 146(52):2552-6. PubMed ID: 12532670 [TBL] [Abstract][Full Text] [Related]
31. [Human African trypanosomiasis, contributions of experimental models]. Bouteille B; Millet P; Enanga B; Mezui Me J; Keita M; Jauberteau MO; Georges A; Dumas M Bull Soc Pathol Exot; 1998; 91(2):127-32. PubMed ID: 9642464 [TBL] [Abstract][Full Text] [Related]
32. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice. Beland FA Toxic Rep Ser; 1999 Aug; (59):1-66, A1-E7. PubMed ID: 11803702 [TBL] [Abstract][Full Text] [Related]
33. [Complications observed in the treatment of trypanosomiasis in the Congo]. Ginoux PY; Bissadidi N; Frezil JL Med Trop (Mars); 1984; 44(4):351-5. PubMed ID: 6521632 [TBL] [Abstract][Full Text] [Related]
34. [2 epidemics of arsenical encephalopathy in the treatment of trypanosomiasis, Uganda, 1992-1993]. Ancelle T; Barret B; Flachet L; Moren A Bull Soc Pathol Exot; 1994; 87(5):341-6. PubMed ID: 7496198 [TBL] [Abstract][Full Text] [Related]
35. [Melarsoprol]. Simon F Med Trop (Mars); 1999; 59(4):331-2. PubMed ID: 10816741 [No Abstract] [Full Text] [Related]
36. Trypanosoma brucei: lack of cross-resistance to melarsoprol in vitro by cymelarsan-resistant parasites. Scott AG; Tait A; Turner CM Exp Parasitol; 1997 Jul; 86(3):181-90. PubMed ID: 9225768 [TBL] [Abstract][Full Text] [Related]
37. Differential sensitivity of Trypanosoma brucei rhodesiense isolates to in vitro lysis by arsenicals. Yarlett N; Goldberg B; Nathan HC; Garofalo J; Bacchi CJ Exp Parasitol; 1991 Feb; 72(2):205-15. PubMed ID: 1849084 [TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics, metabolism and excretion of megazol in a Trypanosoma brucei gambiense primate model of human African trypanosomiasis. Preliminary study. Enanga B; Ndong JM; Boudra H; Debrauwer L; Dubreuil G; Bouteille B; Chauvière G; Labat C; Dumas M; Périé J; Houin G Arzneimittelforschung; 2000 Feb; 50(2):158-62. PubMed ID: 10719620 [TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetic investigations in patients from northern Angola refractory to melarsoprol treatment. Burri C; Keiser J Trop Med Int Health; 2001 May; 6(5):412-20. PubMed ID: 11348536 [TBL] [Abstract][Full Text] [Related]
40. Effectiveness of a 10-day melarsoprol schedule for the treatment of late-stage human African trypanosomiasis: confirmation from a multinational study (IMPAMEL II). Schmid C; Richer M; Bilenge CM; Josenando T; Chappuis F; Manthelot CR; Nangouma A; Doua F; Asumu PN; Simarro PP; Burri C J Infect Dis; 2005 Jun; 191(11):1922-31. PubMed ID: 15871127 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]